CompletedPhase 2

A Study of NGM621 in Participants With Geographic Atrophy

United States320 participantsStarted 2020-07-22

Plain-language summary

This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.

Who can participate

Age range55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Total GA area must be ≥ 2.5 and ≤ 17.5 mm²
✓. If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm² (0.5 DA), with the overall area of GA ≥ 2.5 and ≤ 17.5 mm²
✓. Well demarcated GA with no anatomical evidence of current or prior CNV in the study eye

What they're measuring

The Rate of Change From Baseline in Geographic Atrophy (GA) Lesion Area

Timeframe: Baseline to Week 52

Number of Participants With Ocular Treatment-emergent Adverse Events in the Study Eye

Timeframe: Baseline to end of study (Week 56)

Trial details

NCT IDNCT04465955

SponsorNGM Biopharmaceuticals, Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-08-16

Results submitted2025-05-19

View on ClinicalTrials.gov More Geographic Atrophy trials